Generic GLP-1 Drugs Enter Market: Doctors Urge Caution and Vigilance

With patents expiring, major Indian pharma companies are preparing to launch significantly cheaper generic versions of popular GLP-1 drugs used for type 2 diabetes and obesity. Leading medical experts, however, are cautioning that strict pharmacovigilance is critical as more Indian population-specific safety data is needed despite the drugs' effectiveness. Dr. V Mohan emphasized that these powerful drugs must only be prescribed under a qualified doctor's supervision to manage potential side effects. The warning follows a CDSCO advisory against pharmaceutical companies promoting these prescription drugs directly to the public.

Key Points: Doctors Warn on Generic GLP-1 Drugs, Stress Pharmaco Vigilance

  • Patent expiry spurs generic GLP-1 drug launches
  • Experts warn of potential side effects, need Indian data
  • CDSCO advisory against public promotion of prescription drugs
  • Drugs must be prescribed and monitored by qualified doctors only
2 min read

"Strict pharmaco vigilance a must, more data needed," caution doctors as generic GLP-1 drugs enter market

As cheaper generic GLP-1 drugs for diabetes and obesity launch, top experts call for strict monitoring and more Indian safety data.

"Strict pharmaco vigilance must be maintained. - Dr V Mohan"

By Shalini Bhardwaj, New Delhi, March 20

With the patent expirations for GLP-1 drugs, used for treating type 2 diabetes and obesity, major Pharma companies in India are lining up cheaper generic alternatives.

These alternatives are likely to be priced at a significantly lower price as compared to the current costs. Acording to the National Family Health Survey (NFHS-5, 2019-21) nearly 24 % of women and 23% of men are overweight or obese, this has resulted in the increase in popularity of GLP-1 drugs.

However, top experts caution that it is critical to ensure strict pharmaco vigilance for these drugs.

Dr V Mohan, renowned diabetologist and Chairman of Dr Mohan's Diabetes Specialities Centre and Madras Diabetes Research Foundation said, "Strict pharmaco vigilance must be maintained."

He also said that these drugs are effective but side effects can occur so more Indian data needs to be collected.

"While they are very effective and fairly safe, side effects can occur but more Indian data needs to be collected."

He further said that these drugs must be prescribed under by qualified doctors,

"This will make it accessible to many more people and quality is important. People are advised to strictly use these drugs under the advice and supervision of a doctor, as these drugs can these drugs are very powerful and can produce side effects also in some people," he said.

Recently , the Central Drugs Standard Control Organisation (CDSCO) had issued a strict advisory warning pharmaceutical companies against promoting prescription weight drugs to the general public. Doctors say this diktat must be followed by all.

"Misleading the public by making false, by making advertisements, by issuing advertisements on these drugs, is not correct, and the DCGI has issued strict advisories about advertising these drugs. They have also rightly mentioned that only a qualified doctor should prescribe these drugs, and not non medical people, like gym trainers, dietitians, etc," said Dr Mohan.

With high demand, falling prices and multiple brands set to hit the GLP-1 market, doctors believe that a caution first approach is a must to ensure patient safety.

- ANI

Share this article:

Reader Comments

S
Sarah B
Dr. Mohan is absolutely right. We need robust Indian data. Our population's physiology and diet are different. Just because it worked in Western trials doesn't guarantee the same safety profile here. Caution is key.
P
Priyanka N
The warning about gym trainers and dietitians prescribing is crucial! In my locality, I've seen wellness coaches casually recommending such medicines. This is dangerous. Strict action should be taken against such malpractice.
R
Rohit P
Lower prices are good, but I hope this doesn't lead to over-prescription. Obesity is a complex issue. Medicines are a tool, not a magic pill. Lifestyle changes are the foundation, which many people want to avoid.
K
Kavya N
CDSCO must ensure they monitor the market closely. With so many brands entering, quality control is paramount. We've seen issues with other generic drugs in the past. Patient safety cannot be compromised for lower cost.
M
Michael C
While I appreciate the caution, let's also acknowledge this as a positive step for healthcare access. Many patients who couldn't afford these treatments now have hope. Responsible use under a doctor's guidance is the way forward.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50